ZA202107300B - Treatment of cutaneous lupus erythematosus - Google Patents

Treatment of cutaneous lupus erythematosus

Info

Publication number
ZA202107300B
ZA202107300B ZA2021/07300A ZA202107300A ZA202107300B ZA 202107300 B ZA202107300 B ZA 202107300B ZA 2021/07300 A ZA2021/07300 A ZA 2021/07300A ZA 202107300 A ZA202107300 A ZA 202107300A ZA 202107300 B ZA202107300 B ZA 202107300B
Authority
ZA
South Africa
Prior art keywords
lupus erythematosus
cutaneous lupus
treatment
oxopropanenitrile
diazaspiro
Prior art date
Application number
ZA2021/07300A
Other languages
English (en)
Inventor
Nielsen Jacob
Pommergaard Pedersen Gitte
Mortensen Helene
Sander Camilla
Klie Refer Pia
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of ZA202107300B publication Critical patent/ZA202107300B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2021/07300A 2019-05-15 2021-09-28 Treatment of cutaneous lupus erythematosus ZA202107300B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19174586 2019-05-15
PCT/EP2020/063518 WO2020229622A1 (en) 2019-05-15 2020-05-14 Treatment of cutaneous lupus erythematosus

Publications (1)

Publication Number Publication Date
ZA202107300B true ZA202107300B (en) 2025-12-17

Family

ID=66554234

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/07300A ZA202107300B (en) 2019-05-15 2021-09-28 Treatment of cutaneous lupus erythematosus

Country Status (15)

Country Link
US (2) US20220241284A1 (https=)
EP (1) EP3968997B1 (https=)
JP (2) JP7734587B2 (https=)
KR (1) KR20220008893A (https=)
CN (1) CN113825512A (https=)
AU (1) AU2020275208B2 (https=)
BR (1) BR112021022031A2 (https=)
CA (1) CA3137247A1 (https=)
IL (1) IL288011A (https=)
MX (1) MX2021012874A (https=)
SG (1) SG11202110777XA (https=)
TW (1) TWI863995B (https=)
UA (1) UA129431C2 (https=)
WO (1) WO2020229622A1 (https=)
ZA (1) ZA202107300B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202989A1 (en) 2022-04-20 2023-10-26 Leo Pharma A/S Treatment of frontal fibrosing alopecia
WO2024194105A1 (en) * 2023-03-17 2024-09-26 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8883838B2 (en) * 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2016112208A2 (en) * 2015-01-09 2016-07-14 Kineta One, Llp Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
PT3297605T (pt) * 2015-05-21 2022-05-30 Dermavant Sciences GmbH Composições farmacêuticas tópicas
DK3405197T3 (da) * 2016-01-21 2023-11-27 Leo Pharma As Topisk behandling af håndeksem

Also Published As

Publication number Publication date
AU2020275208A1 (en) 2021-10-28
UA129431C2 (uk) 2025-04-23
JP2025114800A (ja) 2025-08-05
KR20220008893A (ko) 2022-01-21
CN113825512A (zh) 2021-12-21
EP3968997B1 (en) 2026-03-18
EP3968997A1 (en) 2022-03-23
BR112021022031A2 (pt) 2021-12-28
AU2020275208B2 (en) 2025-12-04
US20260069595A1 (en) 2026-03-12
TWI863995B (zh) 2024-12-01
WO2020229622A1 (en) 2020-11-19
CA3137247A1 (en) 2020-11-19
TW202106690A (zh) 2021-02-16
JP7734587B2 (ja) 2025-09-05
JP2022533526A (ja) 2022-07-25
SG11202110777XA (en) 2021-11-29
MX2021012874A (es) 2021-11-17
US20220241284A1 (en) 2022-08-04
IL288011A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
ZA202107300B (en) Treatment of cutaneous lupus erythematosus
MX2022006466A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune.
DK2840080T3 (da) Nitrogenholdig heterocyklisk forbindelse eller salt deraf
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12013502090A1 (en) 1,3 oxazines as bace1 and/or bace2 inhibitors
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
PH12019502365A1 (en) New bicyclic pyrazole derivatives
PH12022551359A1 (en) Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
AU2018251118A8 (en) Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof
EP4397375A3 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
CY1126388T1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MX2009008084A (es) Derivados de 5,6,7,8-tetrahidropteridina como inhibidores de hsp90.
EA201270615A1 (ru) Противогрибковый препарат, содержащий грибковый организм
NZ605860A (en) Use of vitamin c, and chromium-free vitamin k or 2-methyl-1,4-naphthalendione, and compositions thereof for treating a polycystic disease
MA57202B1 (fr) Compositions d'activation de la pyruvate kinase r (pkr)
MX2024013266A (es) Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina
ZA201801722B (en) Treatment of alopecia areata
PH12019502580B1 (en) Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio
MX2024004738A (es) Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas.
BR112021000183A8 (pt) Preparação medicinal para uso externo
PH12021550093A1 (en) Compounds for use in the treatment of fascioliasis
NZ740690B2 (en) Treatment of alopecia areata